Physostigmine-induced myoclonus in Alzheimer’s disease

Richard Mayeux, Marilyn Albert, Michael Jenike

Research output: Contribution to journalArticlepeer-review


Physostigmine caused myoclonus in two patients with Alzheimer’s disease during a clinical trial. Neither patient had myoclonus before or after physostigmine treatment. We hypothesize that physostigmine reduced the sensitivity of the remaining muscarinic receptors in these two patients, altering the interaction between cholinergic and either serotoninergic or dopaminergic neurotransmitter systems.

Original languageEnglish (US)
Pages (from-to)345-346
Number of pages2
Issue number2
StatePublished - Feb 1987
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Physostigmine-induced myoclonus in Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this